Dear John,

Yesterday, we released our October issue focusing on children, Medicare, pharmaceuticals, and more.

Order your copy and become a subscriber today!

Today's Featured Articles

Postapproval Innovation For Oncology Drugs And The Inflation Reduction Act

Henry Grabowski et al.

Proposed 2026 Payment Notice: Marketplace Standards And Insurance Reforms

Sabrina Corlette and Jason Levitis

Does Higher Spending On Primary Care Lead To Lower Total Health Care Spending?

Gary Swan et al.

More on the Inflation Reduction Act

The Joint Distribution Of High Out-Of-Pocket Burdens, Medical Debt, And Financial Barriers To Needed Care

Didem M. Bernard et al. (November 2023)

The Affordability Of Individual-Market Health Insurance In California Under The American Rescue Plan Act, 2021

Vicki Fung et al. (July 2023)

Trends In Medical And Pharmacy Spending In The Affordable Care Act Markets, 2015–19

Nathaniel G. Jacobson et al. (February 2023)

Pragya Kakani on How Protected-Class Policy Impacts Medicare Drug Rebates

Health Affairs' Editor-in-Chief Alan Weil interviews Pragya Kakani of Cornell University about her recent paper exploring the association between Medicare Part D protected-class policy and lower drug rebates.

As we get closer to election day, Health Affairs is collecting articles we've published over the years to reflect on evidence and analysis on the health-related topics that could shape either party's platform. 

The topics range from the Affordable Care Act to antitrust to reproductive health and more.

To look back at what we've covered thus far, learn more at our Election 2024 resource hub.

Rachel Sachs Explains the FTC's Pharmacy Benefit Manager Lawsuit & PBM Reform

Health Affairs' Jeff Byers is joined by Deputy Editor Chris Fleming and Rachel Sachs of Washington University, St. Louis to discuss a recent lawsuit filed by the Federal Trade Commission (FTC) against the three largest pharmacy benefit managers (PBMs) in the country for rebating practices that the FTC claims resulted in inflating the list price of insulin.

“Low- And Middle-Income Countries Experienced Delays Accessing New Essential Medicines”

Join Health Affairs October 21 for a virtual event examining the timing of new drug launches in low-, middle-, and high-income markets from 1982 to 2024.

This event is exclusive to Health Affairs Insiders.